DK235584D0 - Fremgangsmaade til fremstilling af et valleprodukt - Google Patents

Fremgangsmaade til fremstilling af et valleprodukt

Info

Publication number
DK235584D0
DK235584D0 DK2355/84A DK235584A DK235584D0 DK 235584 D0 DK235584 D0 DK 235584D0 DK 2355/84 A DK2355/84 A DK 2355/84A DK 235584 A DK235584 A DK 235584A DK 235584 D0 DK235584 D0 DK 235584D0
Authority
DK
Denmark
Prior art keywords
citrate
procedure
manufacturing
wheel product
product
Prior art date
Application number
DK2355/84A
Other languages
English (en)
Inventor
Olivier De Rham
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4237743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK235584(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of DK235584D0 publication Critical patent/DK235584D0/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C21/00—Whey; Whey preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/08—Dairy proteins

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Water Supply & Treatment (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dairy Products (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Braking Arrangements (AREA)
DK2355/84A 1983-05-13 1984-05-11 Fremgangsmaade til fremstilling af et valleprodukt DK235584D0 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH261583 1983-05-13

Publications (1)

Publication Number Publication Date
DK235584D0 true DK235584D0 (da) 1984-05-11

Family

ID=4237743

Family Applications (1)

Application Number Title Priority Date Filing Date
DK2355/84A DK235584D0 (da) 1983-05-13 1984-05-11 Fremgangsmaade til fremstilling af et valleprodukt

Country Status (17)

Country Link
US (1) US4748034A (da)
EP (1) EP0126290B2 (da)
JP (1) JPS59216544A (da)
AT (1) ATE24658T1 (da)
AU (1) AU564405B2 (da)
CA (1) CA1200416A (da)
DE (1) DE3461886D1 (da)
DK (1) DK235584D0 (da)
ES (1) ES8506983A1 (da)
GB (1) GB2139630B (da)
HK (1) HK73787A (da)
KE (1) KE3728A (da)
MX (1) MX167579B (da)
MY (1) MY100729A (da)
NZ (1) NZ208086A (da)
SG (1) SG35687G (da)
ZA (1) ZA843213B (da)

Families Citing this family (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672230A5 (da) * 1987-10-15 1989-11-15 Nestle Sa
FR2634104B1 (fr) * 1988-07-18 1991-10-18 Union Coop Agricole Hydrolysat partiel de proteines de lactoserum, procede enzymatique de preparation de cet hydrolysat, et aliment lacte dietetique hypoallergenique le contenant
DE4002204A1 (de) * 1990-01-26 1991-08-01 Westfalen Milchwerke Diaetetisches nahrungsmittel fuer patienten mit niereninsuffizienz
NL9001692A (nl) * 1990-04-26 1991-11-18 Cooeperatieve Melkproductenbed Werkwijze voor de bereiding van een olie-in-water emulsie.
JP3065116B2 (ja) * 1991-02-25 2000-07-12 株式会社第一化成 透明な乳清タンパク質加工品の製造法
JP3059595B2 (ja) * 1992-11-20 2000-07-04 森永乳業株式会社 沈澱を生じない乳清蛋白質分解物の製造法
US5350590A (en) * 1992-12-15 1994-09-27 Beatreme Foods Inc. Protein fat replacer and method of manufacture thereof
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
EP2305235A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
WO2000003745A2 (en) 1998-07-15 2000-01-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6106874A (en) * 1998-11-18 2000-08-22 Abbott Laboratories Calcium fortified juice-based nutritional supplement and process of making
KR100815661B1 (ko) * 2000-02-17 2008-03-20 웰치 후드스, 인코포레이티드 칼슘-강화된 포도 기재 제품 및 그의 제조 방법
WO2001066772A2 (en) 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
EP1328261A2 (en) * 2000-04-12 2003-07-23 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
RU2174756C1 (ru) * 2000-09-18 2001-10-20 Борисов Александр Борисович Пищевой продукт
DE10062056A1 (de) * 2000-12-15 2002-07-04 Henkel Ecolab Gmbh & Co Ohg Verfahren zur Reinigung von Ionenaustauscher-Kunststoffharzen
TW200300696A (en) 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
ATE369045T1 (de) * 2001-11-26 2007-08-15 Nestec Sa Lagerstabiles nahrungsmittelprodukt enthaltend molkenprotein, verfahren zu seiner herstellung und verwendung
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
EP1518120A4 (en) * 2002-03-11 2008-08-13 Momenta Pharmaceuticals Inc ANALYSIS OF SULFATE POLYSACCHARIDES
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
JP3833129B2 (ja) * 2002-03-19 2006-10-11 株式会社Ａｄｅｋａ 濃縮牛乳状組成物
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
MXPA05007154A (es) 2002-12-30 2005-09-21 Nektar Therapeutics Atomizador prepeliculizacion.
US7399496B2 (en) * 2003-02-07 2008-07-15 Glanbia Nutritionals (Ireland) Limited Hydrolyzed whey protein compositions
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
WO2004111199A2 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
JP2007502991A (ja) 2003-08-20 2007-02-15 バイオサイト インコーポレイテッド 生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
US7355593B2 (en) * 2004-01-02 2008-04-08 Smart Technologies, Inc. Pointer tracking across multiple overlapping coordinate input sub-regions defining a generally contiguous input region
US20050163887A1 (en) * 2004-01-23 2005-07-28 Land O' Lakes, Inc. Method of producing heat stable whey protein and products made therefrom
US20070172474A1 (en) * 2004-04-02 2007-07-26 University Of Tennessee Research Foundiation Dairy components effective for fat loss
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
EP2338994B1 (en) 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
NZ537456A (en) * 2004-12-24 2007-10-26 Fonterra Co Operative Group Whey products and a process for preparing a modified whey protein concentrate
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
WO2006110731A2 (en) * 2005-04-11 2006-10-19 University Of Tennessee Research Foundation Stable dairy components effective for fat loss
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
AU2006270066A1 (en) 2005-07-19 2007-01-25 University Of Tennessee Research Foundation LPA2 receptor agonist inhibitors of CFTR
CA2616537A1 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009509128A (ja) * 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CA2631731A1 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
CL2007002167A1 (es) * 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
US20100092480A1 (en) * 2006-10-13 2010-04-15 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
CN101711287B (zh) 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
JP2009000091A (ja) * 2007-06-25 2009-01-08 Sanei Gen Ffi Inc 抱気性乳清タンパク質の調製方法及び該方法によって調製される食品
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
US20090233858A1 (en) * 2008-02-26 2009-09-17 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
WO2009111375A2 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
AU2009244267A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by miRNA
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
WO2010033958A1 (en) * 2008-09-22 2010-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
AU2010238723A1 (en) 2009-04-23 2011-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
EP2432466B1 (en) 2009-04-30 2018-03-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Schweinfurthins and uses thereof
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
IN2012DN00352A (da) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2817779T3 (es) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012125623A2 (en) 2011-03-14 2012-09-20 Ludwig Institute For Cancer Research Ltd. Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
TR201815488T4 (tr) 2011-04-08 2018-11-21 Health Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı.
JP6170906B2 (ja) 2011-04-21 2017-07-26 トラスティーズ・オブ・タフツ・カレッジＴｒｕｓｔｅｅｓ Ｏｆ Ｔｕｆｔｓ Ｃｏｌｌｅｇｅ 活性物質を安定化させるための組成物および方法
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2734843A2 (en) 2011-07-18 2014-05-28 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
EP2739734A1 (en) 2011-08-03 2014-06-11 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Treatment of fibrosis using microrna-19b
WO2013058809A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
IN2014CN02906A (da) 2011-10-20 2015-07-03 Us Health
WO2013082000A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
US9894911B2 (en) 2012-06-15 2018-02-20 Morinaga Milk Industry Co., Ltd. Method for manufacturing modified whey composition
CA2881818A1 (en) 2012-08-21 2014-02-27 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
RU2658485C2 (ru) 2012-10-24 2018-06-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы м971
DK2730170T3 (da) 2012-11-13 2016-05-30 Dmk Deutsches Milchkontor Gmbh Allergenfrie næringsmiddelsammensætninger
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
WO2014093711A1 (en) 2012-12-12 2014-06-19 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
EP3919070B1 (en) 2013-03-14 2024-10-16 Children's Medical Center Corporation Use of cd36 to identify cancer subjects for treatment by a psap peptide
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
KR102457668B1 (ko) 2013-03-15 2022-10-21 트러스티즈 오브 터프츠 칼리지 저분자량 실크 조성물 및 안정화 실크 조성물
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
EP2981280A2 (en) 2013-04-04 2016-02-10 IEO - Istituto Europeo di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
MX381320B (es) 2013-06-25 2025-03-12 Walter & Eliza Hall Inst Medical Res Usos de antagonistas de iap en infecciones intracelulares.
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
RU2701346C1 (ru) 2013-12-06 2019-09-25 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
MY186968A (en) 2013-12-16 2021-08-26 Nestle Sa Newly identified peptides for use in the induction of oral tolerance in young mammals
EP3546474B1 (en) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
JP6727129B2 (ja) 2014-03-26 2020-07-22 ザ チルドレンズ メディカル センター コーポレーション 環状プロサポシンペプチドおよびその使用
EP3139909B1 (en) 2014-05-09 2025-01-01 Yale University Hyperbranched polyglycerol-coated particles
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3193933B1 (en) 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
JP6952685B2 (ja) 2015-06-05 2021-10-20 アイバイオ・インコーポレイテッドＩｂｉｏ， Ｉｎｃ． 線維症の治療において使用するためのエンドスタチン断片およびバリアント
EP3109257B1 (en) 2015-06-26 2021-01-06 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
EP3313519B1 (en) 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
US10806170B2 (en) 2015-12-18 2020-10-20 Societe Des Produits Nestle S.A. Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate
EP3405496B1 (en) 2016-01-20 2023-10-25 University of Florida Research Foundation, Incorporated Ror1 antibody compositions and related methods
CN109311982A (zh) 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
MX2018012719A (es) 2016-04-19 2019-05-30 Us Health Ram negativas para tratar la dermatitis atopica.
EP4092045A1 (en) 2016-05-16 2022-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
CA3025516A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
WO2018005799A1 (en) 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
EP3484304B1 (en) * 2016-07-15 2020-09-02 Arla Foods Amba Method of producing concentrated or dried acid-gellable whey protein aggregates, and related compositions and food products
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
EP3655437A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Human antibodies binding to ror2
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
EP3777567A4 (en) * 2018-03-30 2022-01-26 Megmilk Snow Brand Co. Ltd. METHOD OF PREPARING A COMPOSITION CONTAINING KAPPA-CASEINGLYCOMACROPEPTIDE
CA3099903A1 (en) 2018-05-11 2019-11-14 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
US20210267238A1 (en) 2018-06-27 2021-09-02 Arla Foods Amba Instant beverage powder based on blg
CN109045278B (zh) * 2018-07-09 2022-06-21 苏州恒瑞健康科技有限公司 一种稳定的乳蛋白质液态体系及其应用
EP3860635A4 (en) 2018-10-04 2022-07-06 Rutgers, The State University of New Jersey METHOD OF REDUCING TYPE 2 CYTOKINE MEDIATED INFLAMMATION WITH NEUROMEDIN PEPTIDES
US11266617B2 (en) 2018-10-16 2022-03-08 Massachusetts Institute Of Technology Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
CN117925571A (zh) 2018-10-19 2024-04-26 德克萨斯州大学系统董事会 工程化长散在元件（line）转座子及其使用方法
CN113226465A (zh) 2018-12-19 2021-08-06 雀巢产品有限公司 用于预防或减少经皮水分流失并改善皮肤屏障功能的组合物
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
PH12021551676A1 (en) 2019-01-18 2022-03-07 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
CN113711316A (zh) 2019-01-30 2021-11-26 詹森药业有限公司 基于分子亚型治疗前列腺癌的方法
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CA3136618A1 (en) 2019-04-10 2020-10-15 Elevatebio Technologies, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状ｒｎａ組成物及び方法
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
UY38800A (es) 2019-07-26 2021-01-29 Janssen Biotech Inc Receptor de antígeno quimérico (car) anti-hk2
TWI894157B (zh) 2019-07-26 2025-08-21 美商健生生物科技公司 包含血管舒緩素相關肽酶２抗原結合域之蛋白質及其用途
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
EP4013883A1 (en) 2019-08-16 2022-06-22 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
EP4061837A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
ES2980760T3 (es) 2019-12-30 2024-10-03 Arla Foods Amba Método de producción de nanogeles de proteína de suero de leche densos, los nanogeles o composiciones de nanogeles de proteína de suero de leche resultantes, y uso de tales nanogeles o composiciones de nanogeles de proteína de suero de leche
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
AU2021225926A1 (en) 2020-02-26 2022-10-20 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
KR20230051617A (ko) 2020-03-13 2023-04-18 얀센 바이오테크 인코포레이티드 Siglec-3/cd33을 결합시키기 위한 물질 및 방법
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
US20240042015A1 (en) 2020-05-19 2024-02-08 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
MX2023004395A (es) 2020-10-16 2023-05-22 Univ Georgia Glicoconjugados.
CA3214259A1 (en) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
EP4392455A4 (en) 2021-08-25 2025-08-20 Ibio Inc ANTI-CD-25 ANTIBODIES
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
CN118541346A (zh) 2021-11-08 2024-08-23 奥纳治疗公司 用于递送环状多核苷酸的脂质纳米颗粒组合物
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
EP4634390A2 (en) 2022-12-15 2025-10-22 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases
WO2026068747A1 (en) 2024-09-26 2026-04-02 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Astrocytic phosphoprotein (pea-15) for use in the treatment and/or prevention of a neuronal disorder
EP4729541A1 (en) 2024-10-16 2026-04-22 Paolo Fiorina Anti- igfbp7 antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1085380A (en) * 1913-03-28 1914-01-27 Adam Thomas Bell Whey emulsion.
US1609617A (en) * 1926-06-15 1926-12-07 William O Frohring Method of increasing the coagulating point of milk
US1954769A (en) * 1930-12-08 1934-04-10 M & R Dietetic Lab Inc Treating milk products
US2570231A (en) * 1946-01-04 1951-10-09 Hansen Francis Frederick Condensed milk composition and its preparation
US2555514A (en) * 1947-01-20 1951-06-05 Golden State Company Ltd Whey product derived from milk and process of producing same
FR1523106A (fr) * 1962-06-15 1968-05-03 Afico Sa Lait en poudre pour nourrissons et son procédé de fabrication
DE1692294A1 (de) * 1966-09-14 1971-07-29 United Brands Co Verfahren zur Stabilisierung kondensierter Milch
US3791283A (en) * 1970-08-28 1974-02-12 Gen Foods Corp Method for producing heat and acid stable whey protein material
DE2138277C2 (de) * 1971-07-30 1982-09-16 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Verfahren zur Herstellung eines Molkeeiweißkonzentrates
CH556143A (fr) * 1972-09-11 1974-11-29 Nestle Sa Procede de preparation d'une fraction soluble des proteines du petit lait.
NL7603369A (en) * 1976-03-31 1977-10-04 Stichting Bedrijven Van Het Selective removal of inorganic ions from aq. protein concentrates - by ultrafiltration and diafiltration at controlled pH
FR2391653A1 (fr) * 1977-05-23 1978-12-22 Nestle Sa Soc Ass Tech Prod Procede de traitement du lactoserum
NL181326C (nl) * 1979-11-20 1987-08-03 Stichting Bedrijven Van Het Werkwijze voor de bereiding van voedingsmiddelen waarin een in water oplosbare gedenatureerde wei-eiwitsamenstelling wordt opgenomen alsmede werkwijze ter bereiding van oplosbare gedenatureerde wei-eiwitsamenstellingen.
US4460615A (en) * 1981-10-02 1984-07-17 Kyowa Hakko Kogyo Kabushiki Kaisha Process for improving the quality of whey protein
JPS603814B2 (ja) * 1981-10-02 1985-01-30 協和醗酵工業株式会社 改質ホエ−蛋白貿の製造法
US4497836A (en) * 1982-08-06 1985-02-05 Dairy Technology Ltd. Modified whey product and process including ultrafiltration and demineralization

Also Published As

Publication number Publication date
ZA843213B (en) 1984-12-24
EP0126290A1 (fr) 1984-11-28
GB8411196D0 (en) 1984-06-06
ES532469A0 (es) 1985-09-01
JPS59216544A (ja) 1984-12-06
AU2755184A (en) 1984-11-15
JPS646739B2 (da) 1989-02-06
DE3461886D1 (en) 1987-02-12
KE3728A (en) 1987-06-05
CA1200416A (en) 1986-02-11
MX167579B (es) 1993-03-30
SG35687G (en) 1988-09-23
GB2139630B (en) 1987-01-07
MY100729A (en) 1991-01-31
ES8506983A1 (es) 1985-09-01
GB2139630A (en) 1984-11-14
HK73787A (en) 1987-10-16
EP0126290B1 (fr) 1987-01-07
NZ208086A (en) 1986-06-11
ATE24658T1 (de) 1987-01-15
EP0126290B2 (fr) 1994-03-30
AU564405B2 (en) 1987-08-13
US4748034A (en) 1988-05-31

Similar Documents

Publication Publication Date Title
DE3461886D1 (en) Process for preparing a whey product
PH23256A (en) A process for the preparation of quinolone carboxylic acid derivatives
DE3567463D1 (en) 4-dimethylamino-1-hydroxybutane-1,1-diphosphonic acid, its water soluble salts, process for their preparation and its use
NO843002L (no) Vandig loesning inneholdende en lipid-loeselig farmasoeytisk substans
AU587365B2 (en) Pasteurized human fibrinogen (HF), a process for its preparation and its use
ES416597A1 (es) Procedimiento de preparacion de albumina purificada.
IL64396A0 (en) Process for the production of bloodclotting factors and preparation of factors ix and x prepared by this process
ATE114319T1 (de) Produktion von proteinen in aktiven formen.
CA2040496A1 (en) Method for preparing an aqueous food supplement for cattle and thus prepared food supplement
ATE31379T1 (de) Verfahren zur herstellung einer magermilch.
BG38489A3 (en) Method for preparing oxazophosphorine- 6, 4- thiolcalsulphonic acids and their neutral salts
ATE26213T1 (de) Aeusserlich anzuwendende arzneimittelzubereitung enthaltend adenosin zur behandlung von herpes.
AU558927B2 (en) Gelled gelatin food product
HUT41375A (en) Process for producing cristalline glutaminic acid, first of all as monosodium salt, and process for producing salts and organic concentrate produced during the process
JPS56128711A (en) Glucose-electrolyte preparation for high-calorie transfusion
ES450053A1 (es) Un procedimiento para elaborar un producto de proteina tex- turizada.
BG31214A3 (en) Method for obtaining of human albumine
FR2348700A1 (fr) Procede pour la preparation de derives para-substitues de l'acide alpha-phenyl-propionique,ainsi que ces derives
JPS5428791A (en) Process for purifying aqueous solution of calcium salt
JPS5685250A (en) Preparation of novel protein material
ES8604393A1 (es) Procedimiento para la preparacion del citrato del (+) (3x, 16x)-eburnamenina-14-carboxilato de metilo
JPS5428796A (en) Process for producing pure anhydrous dicalcium phosphate
ES8505676A1 (es) Procedimiento para la preparacion del fosfato del (+) 14, 15-dehidro-(3 , 16 )-eburnamenina-14-carboxilato de etilo
ZA885785B (en) Process for the preparation of n6-benzyloxycarbonyl-2,6-diaminopimelamic acid in the l,l or d,d or racemic forms
ES8405359A1 (es) Procedimiento para preparar derivados farmaceuticamente aceptables de 2-dietilamino-metiletil-cis-1-hidroxi-(biciclohexil)-2-carboxilato.

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
ARF Application refused